The role of tyrosine kinases in the responses of human neutrophils to chemotactic factors was examined using the recently described inhibitor erbstatin. Pre-incubation with erbstatin decreased the amount of tyrosine phosphorylation induced by the formylated oligopeptide formylmethionyl-leucyl-phenylalanine (fMet-Leu-Phe) without effecting the binding of [3H]-fMet-Leu-Phe. Erbstatin also dose-dependently inhibited the production of superoxide anion induced by fMet-Leu-Phe and platelet-activating factor, but did not affect the oxidative burst induced by either the calcium ionophore A23187 or the phorbol ester phorbol 12-myristate 13-acetate. Furthermore, erbstatin diminished the cytosolic acidification elicited by fMet-LeuPhe, platelet-activating factor, and leukotriene B, . In con-F T H E THREE major signaling pathways known to be 0 involved in cellular responses to various hormones and other soluble stimuli, only that dependent on the phosphatidylinositol 4,5-bisphosphate-specific phospholipase C has been firmly implicated in the initiation of the responses of neutrophilic polymorphonuclear leukocytes (neutrophils) (for reviews, see 1,2). Cyclic nucleotides play only modulatory roles by exerting positive (cyclic GMP3) or negative (cyclic AMP4) influences on the initiation of neutrophil responsiveness. Little, if any, information is available concerning the role of tyrosine protein kinases in the chemotactic factorstimulated functions of the neutrophils. However, evidence has recently been obtained indicating that neutrophil stimulation by chemotactic factors is associated with tyrosine pho~phorylation.~'~ Tyrosine phosphorylation has been intimately related to the mechanism of action of several growth factors, the tyrosine kinase often forming an integral part of the receptor molec~le(s).~ Examples of these include epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin and insulin-like growth factor, several of which (eg, insulin and PDGF) are known to interact with the neutrophils. Furthermore, a link between the epidermal growth factor-stimulated tyrosine kinase activity and the hydrolysis of phosphatidylinositol 4,5-bisphosphate has recently been suggested in the epidermoid carcinoma cell line A43 1 ." These results raise the possibility that a relationship between the tyrosine kinase and the phospholipase C signaling pathways may exist in other cells such as neutrophils. Additional evidence of a role for tyrosine kinases in the responses of neutrophils to chemotactic factors has also been recently obtained. Gomez-Cambronero et a1' and Berkow et ale have reported that a tyrosine kinase inhibitor ST638 inhibited formyl-methionyl-leucyl-phenylalanine (Met-LeuPhe)-induced superoxide production in human neutrophils. However, the significance of the latter findings is clouded by the finding of Berkow et ala that ST638 potently inhibited the binding of Met-Leu-Phe to human neutrophils. The present investigations were initiated to examine the potential functional significance of the chemotactic factorstimulated tyrosine phosphorylation in human neutrophils. We have addressed this question by taking advantage of the inhibitory properties of erbstatin, a compound isolated from culture filtrates of Streptomyces viridosporus that has recently been shown to be a potent and specific inhibitor of tyrosine protein kinases.".'* The results demonstrate that erbstatin selectively inhibits the activation of the oxidative burst and the cytosolic acidification induced by chemotactic factors in human neutrophils without affecting the stimulated mobilization of calcium, polymerization of actin or degranulation. Thus, tyrosine protein kinases may play important roles in the activation of specific functions of human neutrophils by chemotactic factors.
F T H E THREE major signaling pathways known to be 0 involved in cellular responses to various hormones and other soluble stimuli, only that dependent on the phosphatidylinositol 4,5-bisphosphate-specific phospholipase C has been firmly implicated in the initiation of the responses of neutrophilic polymorphonuclear leukocytes (neutrophils) (for reviews, see 1,2). Cyclic nucleotides play only modulatory roles by exerting positive (cyclic GMP3) or negative (cyclic AMP4) influences on the initiation of neutrophil responsiveness. Little, if any, information is available concerning the role of tyrosine protein kinases in the chemotactic factorstimulated functions of the neutrophils. However, evidence has recently been obtained indicating that neutrophil stimulation by chemotactic factors is associated with tyrosine pho~phorylation.~'~ Tyrosine phosphorylation has been intimately related to the mechanism of action of several growth factors, the tyrosine kinase often forming an integral part of the receptor molec~le(s).~ Examples of these include epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin and insulin-like growth factor, several of which (eg, insulin and PDGF) are known to interact with the trast, erbstatin was without effect on the increase in the levels of cytoplasmic free calcium and polymerized actin elicited by fMet-Leu-Phe, C5,. leukotriene B, and plateletactivating factor, whereas the increase in cytoplasmic free calcium elicited by platelet-derived growth factor was inhibited by erbstatin. In addition, erbstatin affected neither the release of elastase stimulated by these agonists nor the release of 0-glucosaminidase, lysozyme or vitamin B12-binding protein induced by fMet-Leu-Phe. These results indicate that tyrosine protein kinases are involved in the signaling pathways employed by chemotactic factors in the stimulation of selective functional responses (and superoxide production in particular) in human neutrophils. 0 1990 by The American Society of Hematology.
neutrophils. Furthermore, a link between the epidermal growth factor-stimulated tyrosine kinase activity and the hydrolysis of phosphatidylinositol 4,5-bisphosphate has recently been suggested in the epidermoid carcinoma cell line A43 1 ." These results raise the possibility that a relationship between the tyrosine kinase and the phospholipase C signaling pathways may exist in other cells such as neutrophils. Additional evidence of a role for tyrosine kinases in the responses of neutrophils to chemotactic factors has also been recently obtained. Gomez-Cambronero et a1' and Berkow et ale have reported that a tyrosine kinase inhibitor ST638 inhibited formyl-methionyl-leucyl-phenylalanine (Met-LeuPhe)-induced superoxide production in human neutrophils. However, the significance of the latter findings is clouded by the finding of Berkow et ala that ST638 potently inhibited the binding of Met-Leu-Phe to human neutrophils.
The present investigations were initiated to examine the potential functional significance of the chemotactic factorstimulated tyrosine phosphorylation in human neutrophils. We have addressed this question by taking advantage of the inhibitory properties of erbstatin, a compound isolated from culture filtrates of Streptomyces viridosporus that has recently been shown to be a potent and specific inhibitor of tyrosine protein kinases.".'* The results demonstrate that erbstatin selectively inhibits the activation of the oxidative burst and the cytosolic acidification induced by chemotactic factors in human neutrophils without affecting the stimulated mobilization of calcium, polymerization of actin or degranulation. Thus, tyrosine protein kinases may play important roles in the activation of specific functions of human neutrophils by chemotactic factors.
MATERIALS AND METHODS
Human neutrophils were isolated following dextran sedimentation on Ficoll-Paque cushions. The cells were resuspended in Hanks' balanced salt solution (HBSS) (GIBCO, Burlington, Ont), pH 7.4.
The cells were incubated with the indicated concentrations of erbstatin for 1 hpur at 37OC (unless stated otherwise), and washed free of the inhibitor before being tested in any of the following assays.
Intracellular pH was monitored using the fluorescent probe 2,7-biscarboxyethyl-5(6)-carboxyfluorescein (BCECF) as described TYROSINE KINASE AND NEUTROPHIL ACTIVATION 2099 in Faucher and Naccache." Briefly, neutrophil suspensions (1 x lo7 cells/mL) were loaded with BCECF (4 pmol/L, 30-minute incubation at 37OC), washed and their fluorescence measured at 37OC in an SLM 8000 fluorimeter (SLM Instruments Inc, Urbana, IL) (emission and excitation wavelengths, 500 and 530 nm, respectively). Each run was individually calibrated.
Intracellular free calcium was measured using the fluorescent probe fura-2 as previously described." Briefly, neutrophil suspensions (1 x lo7 cells/mL) were loaded with fura-2 (1 pmol/L, 30 minutes at 37OC), washed, and their fluorescence monitored in the fluorimeter (excitation and emission wavelengths, 340 and 5 10 nm, respectively). The internal calcium concentrations were calculated as described in Tsien et aI.l4 Each run was individually calibrated.
Superoxide production was monitored as described in Naccache et alls as the (superoxide dismutase-sensitive) reduction of cytochrome C by a slight modification of the method described in Metcalf et a1.I6
Actin polymerization was measured as detailed in Therrien and Naccache17 by a modification of the NBDphallacidin staining method of Howard and Oresajo.'* Tyrosine phosphorylation was monitored by immunoblotting as described in Huang et als and Gomez-Cambronero et aL6. ' The specificity of the anti-phosphotyrosine antibody documented in previous publication^^^^ includes competition with phosphotyrosine.
The binding of ['HI fMet-Leu-Phe was measured essentially as described in Naccache et al.I9 Briefly, the cells (107/mL) were incubated with the desired concentrations of erbstatin for 1 hour at 37OC, washed twice, resuspended in HBSS, and transferred to an ice-bath. Radiolabeled fMet-Leu-Phe (final concentration, mol/L) was then added to the cells, and the incubation carried out in the ice-bath for 30 minutes. Non-specific binding was estimated as that portion of the binding not displaced by the addition of 2 x lo-' mol/L unlabeled fMet-Leu-Phe. The cells were separated from the suspending media by centrifugation through a silicone oil layer (Versilube F-50, Waterford, NY) in a microcentrifuge. The tube tips containing the cell pellets were cut and transferred to scintillation vials. The pellets were dissolved by the addition of formic acid (88%) (30-minute incubation at room temperature with individual shaking). Liquid scintillation fluid was then added, the pH neutralyzed, and the samples counted.
Neutrophil degranulation was monitored on cells (5 x 106/mL) pre-treated with 5 pg/mL cytochalasin B for 5 minutes. The time course of elastase release was measured as described by Sklar et al.'" Dose-response curves were analyzed using the ALLFIT computer program provided by BCTIC (Nashville, TN). Briefly, the cells were exposed to varying concentrations of chemotactic factors for 5 minutes at 37OC, transferred to an ice-bath and then centrifuged for 5 minutes at 500 x g. The supernatants were collected and their contents in lysozyme, elastase, 0-glucosaminidase and vitamin B12-binding protein analyzed essentially as described in Metcalf et a1" and Sklar et al.'" Platelet-activating factor fMet-Leu-Phe, phorbol 12-myristate 13-acetate (PMA), lysophosphatidylcholine, formalin (40%). cytochrome C and superoxide dismutase were obtained from Sigma Chemical Co, St Louis, MO. Ficoll-Paque was from Pharmacia, Dorval, Qutbec, Canada. BCECF/AM, fura-Z/AM, and NBDphallacidin were obtained from Molecular Probes, Junction City, OR. MeO-Suc-Ala-Ala-Pro-Val-MCA was purchased from Peninsula Laboratories, San Carlos, CA. Cytochalasin B was obtained from Aldrich Chemical Co, Milwaukee, WI. ['HIfMet-Leu-Phe was purchased from DuPont Canada Inc, Markham, Ontario, Canada, and purified on HP-TLC before use. Leukotriene B4, recombinant CSa, and amiloride hydrochloride were generously provided by Drs J. Rokach (Merck-Frosst Canada, Pointe-Claire, Dorval, Canada), C.J. Pazoles (Pfizer Central Research, Groton, CT), and A. Prat (Merck-Frosst Canada, Pointe Claire, Qutbec, Canada), respectively. The concentration of the stock solution of leukotriene B, was determined by UV photometry. Platelet-derived growth factor was purchased from Bachem Inc, Torrance, CA. Erbstatin was purified and characterized as previously described." Stock solutions of erbstatin were made up in DMSO and kept at -7OOC. All the other reagents were of analytical grade.
RESULTS AND DISCUSSION
Erbstatin was isolated from a strain of actinomycetes related to Streptomyces viridosporus by Umezawa et all1 and shown to be a potent inhibitor of tyrosine protein kinase capable of reducing the EGF-stimulated receptor autophosphorylation in isolated membrane preparations of the epidermoid carcinoma cell line A-43 1 ' I as well as the autophosphorylation of p60"" in Rous-sarcoma virus-infected kidney cells.12 Subsequent studies have demonstrated that the inhibitory properties of erbstatin against a partially purified preparation of the EGF receptor associated tyrosine kinase from the A-431 cell line are due to its ability to compete with the substrate of the enzyme, possibly because of its structural similarities to tyrosine." Furthermore, erbstatin is essentially without antagonist activity towards either of protein kinases A or C.22 The inhibitory characteristics of erbstatin make it highly suitable for investigations directed a t the cell-physiologic functions of tyrosine kinases.
The effects of erbstatin on chemotactic factor-stimulated tyrosine phosphorylation in human neutrophils were examined first (Fig 1) . Under the conditions of the assay, the addition of met-Leu-Phe to the cells rapidly and specifically by examining a series of functional and biochemical responses of the cells in the absence and presence of the inhibitor. The aim of these studies was to obtain a profile of the inhibitory activity of erbstatin in order toderive information concerning the role. and site(s) of action. of tyrosine kinases in neutrophil activation and functional responses.
The results depicted in Fig 3 demonstrate that a I-hour incubation with 5 pg/mL erbstatin greatly inhibited the superoxide response of the cells to Met-Leu-Phe. The development of the inhibitory effects of erbstatin was timedependent and reached a maximum at the concentrations tested ( I to 10 pg/mL) following a pre-incubation time of 60 minutes (data not shown). The diminished production of superoxide anions was not due to an increased lag time. It should be pointed out that the effects of erbstatin were not readily reversible. as they were apparent. as demonstrated in not affect the oxidative response to the calcium ionophore A23187 and only weakly (but significantly, P < .OS) inhibited that to PMA at the highest concentration tested. The lack of effect of erbstatin on the response to A23187 (a weak stimulus of the oxidative burst, the maximal response being about one-third that of fMet-Leu-Phe) indicates that erbstatin does not directly interact with the NADPH oxidase. The small effect of 10 fig/mL erbstatin on the response to PMA is intriguing as the phorbol ester is known to stimulate, by presently unknown pathways, tyrosine phosphorylation in neutrophil^,^^ (Naccache et al, unpublished observations) and other cells.23 Furthermore, the ability of A23187 and PMA to bypass the inhibitory effects of erbstatin indicates that the site of action of the inhibitor lies distal (or parallel) to the mobilization of calcium and the activation of protein kinase C. The parallel inhibition of Wet-Leu-Phe-stimulated tyrosine phosphorylation and superoxide production by erbstatin indicates a relationship between these two events. Because it is unlikely that the Met-Leu-Phe receptors possess intrinsic tyrosine kinase activity, the stimulation of the latter is probably distal to the activation of the G protein involved in the signal transduction. Although further investigations are required, this conclusion is supported by the recent demonstration that GTPyS induces both tyrosine phosphorylation and superoxide production in electropermeabilized human neutrophil^,^^ and that pertussis toxin inhibits M e t - Leu-Phe-stimulated tyrosine phosphorylation in rabbit peritoneal neutrophils.' The addition of chemotactic factors to human neutrophils induces biphasic changes in internal pH; a rapid acidification followed by a slower and more sustained alkalinization mediated by the activation of a membrane-located Na+/H' a n t i p~r t . '~.~~.~~ Several recent reports have indicated potential (direct and/or indirect) roles for the rapid acidification at the level of the polymerization of actin, a critical event in the locomotory responses of the neutrophil^,'^.^^.^^, and mobilization of ~a l c i u m .~' Similarly, the stimulated cytoplasmic alkalinization has been reported to play a modulatory role in the control of human neutrophil c h e m~t a x i s .~~ The results shown in panel A of Fig 5 demonstrate that erbstatin decreased the magnitude of the drop in internal pH that follows the addition of Met-Leu-Phe and slowed the rate of alkalinization that followed. Erbstatin also inhibited the drop in cytosolic pH caused by Met-Leu-Phe in amiloride-treated neutrophils (Fig 5, panel B) , ie, under conditions in which the N a + / H + antiport is inhibited and the acidification response is magnified.25,27.28.33.34 The effects of erbstatin were not limited to Met-Leu-Phe as the pH changes elicited by PAF as well as by leukotriene B, were similarly affected upon incubation with the inhibitor (Fig 6) . Evidence for a selective site(s) of action of erbstatin was obtained in experiments in which the effects of the inhibitor on the chemotactic factor-stimulated polymerization of actin and mobilization of calcium were examined. The data summarized in Table 1 demonstrate that neither of these two parameters of neutrophil activation by Met-Leu-Phe was affected by erbstatin (10 pg/mL, 1-hour incubation). A similar lack of effect of erbstatin on calcium mobilization was observed with other neutrophil stimuli such as leukotriene B,, PAF, and recombinant human C5a ( Table 1) . In contrast, erbstatin inhibited to a significant extent (P < .05) the increase in calcium induced by 1.7 nmol/L PDGF reducing the latter from 130 * 16 nmol/L (8) to 56 + 4 nmol/L (4) and 32 f 6 nmol/L (3), control and erbstatin (5 and 10 pg/mL) treated cells, respectively (mean f SEM of the number of determinations indicated in parenthesis). Because the mechanism of action of PDGF depends in part on the tyrosine kinase activity intrinsic to its receptor: this latter set of results, in addition to demonstrating the ability of PDGF to raise cytosolic calcium in human neutrophils, substantiates the activity of erbstatin as a tyrosine kinase inhibitor. Table 2 demonstrate that erbstatin ( 5 pg/mL) had no significant effect on the ED,, or the maximal release of either of the enzyme markers as calculated by ALLFIT. Similarly, no significant changes were noted in the zero intercept or the slope of the doseresponse curves at the inflection point (data not shown). It should be noted however, that in 2 of the 5 experiments performed, erbstatin did induce a partial and non-competitive inhibition of degranulation as evidenced by small but significant decreases (about 40% to 50%) in slopes and maximal release. The reasons for the variability of the responses of the cells to the inhibitor are presently unknown.
These data demonstrate (1) that the inhibition by erbstatin of superoxide generation and of the drop in cytosolic pH was not due to a generalized, non-specific, deleterious action of this compound, and (2) that they cannot be ascribed to interference with the binding of the chemotactic peptide. Furthermore, the ability of erbstatin to inhibit the stimulation of superoxide production by chemotactic factors without affecting the mobilization of calcium mobilization implies that the signaling pathway leading to the former response diverges from the "phospholipase C/polyphosphoinositide cycle" and includes a tyrosine kinase. This observation may provide a basis for the previously observed lack of effect of H-7 (a protein kinase C inhibitor) on the chemotactic factor-stimulated oxidative burst in neutrophil^.^'-^^ The data presented in this paper support the involvement of the tyrosine kinase signaling pathway in the activation of selective functional responses of human neutrophils. In so doing, they indicate that the present conceptual schemes used to describe the cellular physiology of this cell type, which rely entirely on the G proteins-phospholipase C pathway, need to be expanded in scope and modified to include tyrosine protein kinases. 
